E-Learning

3 Reasons KTOS is Risky and 1 Stock to Buy Instead

Even during a down period for the markets, Kratos has gone against the grain, climbing to $28.94. Its shares have yielded a 15.4% return over the last six months, beating the S&P 500 by 26%. This run-up might have investors contemplating their next move.

Read more

3 Reasons to Sell WST and 1 Stock to Buy Instead

West Pharmaceutical Services has gotten torched over the last six months - since October 2024, its stock price has dropped 29.3% to $202.47 per share. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.

Read more

3 Reasons to Avoid ENR and 1 Stock to Buy Instead

Energizer trades at $27.31 per share and has moved almost in lockstep with the market over the last six months. The stock has lost 13.4% while the S&P 500 is down 10.5%. This may have investors wondering how to approach the situation.

Read more

3 Reasons MED is Risky and 1 Stock to Buy Instead

What a brutal six months it’s been for Medifast. The stock has dropped 29.3% and now trades at $13.05, rattling many shareholders. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.

Read more